Effectiveness of the SurePath liquid-based Pap test in automated screening and in detection of HSIL.
We have shown that SurePath when compared to conventional Paps fails to increase HSIL detection. In this study, assessment of test performance characteristics for the FocalPoint showed that sensitivity was 96% when manual screening was used as the "gold standard." When cervical biopsy, however, was used as the "gold standard" FocalPoint sensitivity decreased to 93%, which was the same as manual screening. Examination of the FocalPoint "no further review" cases showed that 4/296 were SIL. To understand better the implication of an SIL diagnosis, cervical biopsies generated from SurePath and conventional Paps were compared. Conventional Paps diagnosed as LSIL had a biopsy LSIL:HSIL ratio of 3.1/1, while SurePath Paps had a biopsy LSIL:HSIL ratio of 1.5/1. These results indicate that when cervical biopsy is used as the "gold standard," FocalPoint and manual screening of SurePath Paps have similar test performance but that the FocalPoint can fail to detect LSIL. Importantly, LSIL in a SurePath Pap is 1.6 times more likely to be HSIL on biopsy than LSIL in a conventional Pap.
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. freun@uiuc.edu
Keith A
KA
Cengel
Sarah J
SJ
Day
Sharon
S
Davis-Devine
Christina L
CL
Adams
Darcy
D
Madison-Henness
Matthew E
ME
Hartman
Gregory G
GG
Freund
D005188:False Negative Reactions; D005260:Female; D006801:Humans; D008403:Mass Screening; D012680:Sensitivity and Specificity; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis*; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*; D014626:Vaginal Smears